No Data
No Data
Candel Therapeutics Advances in Cancer Treatment Trials
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End | NASDAQ:CADL
This Insider Has Just Sold Shares In Candel Therapeutics
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics, Inc. (NASDAQ:CADL) Most Popular Amongst Individual Investors Who Own 48%, Insiders Hold 30%
No Data
No Data